Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer ...
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...
Cboe’s proprietary hedging products can help protect investors in volatile markets amid war-driven oil spikes and supply ...
Company generates record $133 million in free cash flow to support self-funded growth model Orla Mining Ltd. today announces the results for the fourth quarter and year ended 31, 2025. Fourth Quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results